Hepatitis C Increases The Chances Of Parkinson’s

The Hepatitis C virus is connected with Parkinson’s disease. A recent study has proved and issues in a medical magazine. The Parkinson’s disease is the common degenerative brain illness next to Alzheimer’s disease. The liver infection caused due to a virus is Hepatitis C.

Chia-Hung Kao, MD is the research author of the recent finding. He told that several factors remained responsible for the growth of Parkinson’s disease. The environmental condition is also a cause of Parkinson’s disease. The study suggested that hepatitis mainly caused because of Hepatitis C virus have chances to increase the Parkinson’s disease. They added that more research is necessary to conclude the result.

Recently, the WHO (World Health Organisation) took a survey and reported that about one hundred and thirty to one hundred fifty million people are affected by Hepatitis C all over the world. Hepatitis C results in serious illness. Most people experience symptoms that they do not know it is caused because of Hepatitis C but live with the virus. It is identified only it leads to serious medical conditions or illness.

The virus is spread in various forms. Some of the common forms it spreads are needle sharing, the health care physician’s needle stick injuries and transmitting at birth because of infected mothers. The study was performed in Taiwan. It was found that blood transfusion remains as the most common reason for virus transfer. In the United States, the donated blood is tested for the Hepatitis C virus. It was in practice till 1992.

The research involved 199,868 patients without hepatitis and 49,967 patients with hepatitis. They were divided into three categories. One category consists of people with Hepatitis B virus, the second category with people affected with Hepatitis C virus and third category consists of people with both Hepatitis C and Hepatitis B virus. They were followed for about twelve years to see whether Parkinson’s disease developed. The researchers controlled the factors like cirrhosis, diabetes, sex and age and found that people having Hepatitis C are at risk of developing Parkinson’s disease. The risk was not evident in people who did not have Hepatitis.

Moreover, people who have both Hepatitis C and Hepatitis B were not affected with Parkinson’s disease. They were below the risk line. The Taiwan Ministry of Health and Welfare supported the study. Along with them, several health institutions participated and supported the study.

Hepatitis C is a serious medical condition that mainly affects the liver. It is mostly asymptomatic. It can result in cirrhosis. It becomes apparent after several years.

Read More:First Clinical Guidelines Available for Chronic Fungal Lung Illnesses

First Clinical Guidelines Available for Chronic Fungal Lung Illnesses

Lately, the very first guidelines that are available for the chronic fungal lung illnesses for the doctors and laboratories were published by the ERS (European Respiratory Society) and ESCMID (European Society of Clinical Microbiology). These guidelines that are published in the European Respiratory Journal, these guidelines elaborate the most important features of this specific disease, and it also provides highly comprehensive treatment recommendations. The CPA (Chronic Pulmonary Aspergillosis) is an insidious and subtle problem in the patients who already have damaged lungs. This condition has killed almost 80 percent of the sufferers in a time period of five years unless the condition is diagnosed and treated using long term anti-fungals. All through Europe, around 240,000 people are estimated to have CPA and the number accounts to 3 million across the world.

Major enhancements in the understanding of this debilitating and fatal disorder have resulted from the research that has been undertaken in Europe, Japan and India over the last decade. However, no therapies are approved by the EMA (European Medicines Agency) for treatment. However, a few diagnostic tests as well as therapies have been compared with one another. In most parts of the world, even the basic tests that are needed are not available.

As per Professor David Denning at the University of Manchester heading the CPA guidelines group, the UK National Health Service has identified the challenges that are posed by the patients in setting up the National Aspergillosis Center and also its associated laboratory, Mycology Reference Center in the year 2009. The experience is gained by seeing hundreds of patients who have contributed to the quality of care. However, more research and the latest oral antifungal drugs are needed to reduce the market disability that is caused by CPA.

Dr. Marc Miravitlles, the ERS guidelines director, they welcome the publication of these guidelines that provides key insights into the major features of the disease and treatment recommendations. By establishing the expert consensus related to the topic, they aim to enhance the early diagnosis of CPA and also increase the recognition of this condition to improve the outcomes for patients. The guidelines are nothing but a product that is a result of the two-year collaboration between the ERS and ESCMID. The latter is developing wider guidelines right now for invasive aspergillosis, and the same will be published in the course of time. The chairman of EFISG, Andrew Ullmann claims that these guidelines on the chronic pulmonary aspergillosis are a truly interdisciplinary collaboration that is prepared and published for the colleagues available on a group of complex diseases that are very tough to manage.

Read More:Medications that are Approved for Other Purposes Have Antibiotic Actions

Medications that are Approved for Other Purposes Have Antibiotic Actions

Many drugs that are already approved to be used to treat parasitic infections, infertility, cancers and other medical conditions also show up antibiotic properties against tuberculosis infections, and staph, reveals a new study conducted by the chemists and collaborators at the University of Illinois. These agents have the ability to act against several targets within the bacteria, and this might be tougher for the bacteria to develop resistance to persist. This study is led by Eric Oldfield, the Chemistry professor at the university and it was published in the recent edition of Proceedings of the National Academy of Sciences.

Oldfield stated that there is a huge requirement for the use of new antibiotics, and we now have bacteria that are drug resistant as well. The bugs are clever, and they can adapt and look for ways around those that we develop to kill them. In case, the bugs are attacked at multiple targets, it will be very tough for them to little changes to get around the situation. The researchers were interested in looking for compounds that can sabotage the energy production line of bacteria and shutting down the cellular processes that take place within the bacterium. Such agents are called uncouplers, and these were used earlier to treat the parasitic infections.

The researchers were inspired by a leprosy drug called clofazimine that is used to treat tuberculosis, and they searched the drugs that are available and in development to look out for uncouplers that are based on chemical structures. Such multi-target drugs have wide applications against a slew of infections. The researchers searched for other compounds that have similar structures to vacquinol, and they found compounds that are potent antibiotics against Staphylococcus aureus and tuberculosis. Oldfield hopes to build up compounds that are metabolized into the uncouplers that are located in the bacterial cell, and this will further minimize the cross-reactivity with the human cells and make it tougher for the bacteria to build up resistance.

Read More:Hepatitis C Increases The Chances Of Parkinson’s